Management and Outcomes of Pediatric Lymphatic Malformations: A Systematic Review From the APSA Outcomes and Evidence-Based Practice Committee
Timestops (1)
Tools Used
Topic Overview
Key Takeaways
- Sclerotherapy achieves >90% success rate for macrocystic lymphatic malformations based on systematic review of 200 studies (1990-2021).
- Sirolimus is effective for extensive malformations refractory to surgery/sclerotherapy and as initial treatment for airway-compromising lesions.
- Treatment algorithm: observe small asymptomatic lesions; classify large symptomatic lesions as macrocystic/microcystic/mixed before intervention.
- Localized lesions respond well to surgery or sclerotherapy; classification by cyst size guides optimal treatment selection.
- APSA systematic review establishes evidence-based framework for pediatric lymphatic malformation management across multiple modalities.
Keywords
Hashtags
Transcript
What's the best way to treat lymphatic malformations? When is it indicated and how effective is the treatment? I'm Lizzie Lee from Cincinnati Children's Hospital, and this is an article you should know about. Texas Children's Hospital researchers did a systematic review focusing on 200 articles published from 1990 to 2021. They found that sclerotherapy had a success rate of over 90% for macrocystic lesions. Medications like errolimus are helpful for extensive malformations that are refractory to surgery and or sclerotherapy. Cerrolimus is also used as an initial treatment for extensive lymphatic malformations, for example, those that compromise the airway. Small asymptomatic lesions can be observed, while large symptomatic lesions need to be further divided into macrocystic, microcystic, or mixed lesions. If it is a localized lesion, surgery or sclerotherapy is effective. Let us know what you think in the comments below and stay tuned for more articles that you should know about.